Fig. 2From: DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinomaKaplan-Meier plot: second line overall survival time with 95 % confidence interval. OS overall survivalBack to article page